Lunit Inc. (Lunit) aktie
328130.KQ
Fördröjd 20 minLunit
Market Cap
$1,005,653,262,336
Om Lunit Inc. (Lunit) aktie
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Företagsinformation
Seoul, South Korea
Analytikernas aktierekommendationer
Denna översikt ger en snabb insikt i hur analytiker bedömer aktiens potential baserat på deras senaste analyser och kursmål.